Evaluation of glycans profile of human glioma cell lines and their impact in cell biology

HECTOR ADRIÁN CUELLO; GRETEL MAGALÍ FERREIRA; CYNTHIA GULINO; VALERIA INÉS SEGATORI; MARIANO R. GABRI

San Martín

Simposio; 3rd Argentinian Symposium on Glycobiology; 2019

Glioma is the most common primary malignant intracranial tumor with high morbidity and mortality. Little is known about glycosylation and its participation in this indication. Our objective is to describe the glycan profile in human glioma and its participation in cell biology. On a panel of human high and low grade glioma cell lines we evaluated expression of terminalglycans (Lewis and truncated), where SLeX was the major glycan expressed particularly in high grade gliomas. LeY and LeA were also associated with the high grade condition. N-glycans relevance was evaluated by inhibiting their synthesis using TNM and also by silencing MGAT5, which adds β1-6 branching.Participation of core 2 O-glycans on cell behavior was evaluated by silencing their initiating glycosyltransferase C2GNT1. SLeX expression was significantly reduced by TNM treatment on LN229 cells (more than 90%) while C2GNT1 silencing reduced it expression by about 50%. Also, inhibition of N-glycosylation decreased cell adhesion and cell migration to a greater extent than O-glycosylation inhibition in all the cell lines evaluated. High performance anion exchange chromatography analysis of high grade glioma cell lines showed a broad expression of N-glycans with a high abundance of branched tri-antennary structures. The knowledge of glycan structures and their participation in cellbiology can lead us to the identification of new targets for glioblastoma treatments.